Basel Cannabis Study Shows Mental Health Benefits

Two-year 'Weedcare' recreational cannabis study reports reduced depression and anxiety among 300 participants, while consumption levels remain stable.

Key Takeaways

The Weedcare study in Basel is Switzerland's first legal recreational cannabis trial
300 participants showed improved mental health outcomes over two years
Cannabis consumption levels remained stable throughout the study
The study will continue until January 2027

By The Numbers

kilograms of cannabis sold during study

900000

CHF worth of cannabis distributed

8-12

CHF cost per gram

Percent THC content threshold for lower-potency products

They Said

"depressive symptoms and anxiety decreased among the participants"
— Basel City's Department of Health

Groundbreaking Swiss Cannabis Study Shows Promising Mental Health Results

Study Design and Implementation

Key Mental Health Findings

Economic and Market Analysis

Future Implications for Swiss Cannabis Policy

Sources & References

Basel cannabis study reports improvements in smokers' mental health

SWI swissinfo.ch

Key Takeaways

The Weedcare study in Basel is Switzerland's first legal recreational cannabis trial
300 participants showed improved mental health outcomes over two years
Cannabis consumption levels remained stable throughout the study
The study will continue until January 2027